Heart-Targeted Exosome Modification Service
Overview Services Features FAQs
Overview
With the aging population, the morbidity and mortality of cardiovascular disease (CVD) are increasing year by year. In recent years, precisely targeted therapy for CVD has become an inevitable direction for future development. Exosomes have the characteristics of low immunogenicity, low toxicity, and high biocompatibility. They can freely cross biological barriers, escape lysosome-mediated degradation, and transfer biologically active molecules from donor cells to recipient cells. However, natural unmodified exosomes quickly accumulate in the liver, spleen, kidneys, and other organs after infusion. It is difficult for exosomes to accumulate in the heart to effective therapeutic concentrations. Therefore, exosomes need to be modified with cardiac-specific targeting peptides for targeted therapy of CVD. Creative Biolabs can modify the structure of exosomes to enhance the specificity of exosomes targeting cardiac tissue, and then enhance the therapeutic effect of exosomes on CVD.
Heart-targeting Peptides for Engineered Exosomes
Recently, exosome surface display technology is a hot spot in the research field of exosome precision therapy. Using DNA recombination technology, the DNA sequence of the exogenous peptide is fused to the structural gene of the exosome surface protein, so that the exogenous targeting peptide and the surface protein are expressed together. This confers tissue targeting on exosomes. There are currently three proven cardiac tissue-targeting peptides, including ischemic myocardium-targeting peptide CSTSMLKAC (IMTP), cardiomyocyte-specific peptide (CMP), and heart homing peptide (HHP). Through plasmid construction and plasmid transfection techniques, these three polypeptides can be constructed as fusion proteins with lysosome-associated membrane protein 2 (Lamp2b) enriched on the surface of exosomes.
Services
Heart-Targeted Exosome Modification Service
Using DNA recombination technology, the DNA sequence of the exogenous peptide is fused to the structural gene of the exosome surface protein, so that the exogenous targeting peptide and the surface protein are expressed together. This confers tissue targeting on exosomes. There are currently three proven cardiac tissue-targeting peptides, including:
-
Ischemic myocardium-targeting peptide CSTSMLKAC (IMTP)
-
Cardiomyocyte-specific peptide (CMP)
-
Heart homing peptide (HHP)
Through plasmid construction and plasmid transfection techniques, these three polypeptides can be constructed as fusion proteins with lysosome-associated membrane protein 2 (Lamp2b) enriched on the surface of exosomes.
Exosomes modified by the above three cardiac targeting peptides, namely IMTP-Exos, CMP-Exos, and HHP-Exos, can target cardiac tissue more effectively in vivo. IMTP-Exos derived from bone marrow mesenchymal stem cells can be efficiently targeted to the ischemic myocardial tissue, inhibit inflammation, fibrosis, and myocardial cell apoptosis, improve angiogenesis and cardiac function, and have a good therapeutic effect on acute myocardial infarction. Cardiosphere-derived cells (CDCs)-derived CMP-Exos can inhibit cardiomyocyte apoptosis and improve cardiac function after ischemic and non-ischemic myocardial injury. CDCs-derived HHP-Exos can improve cardiac hypertrophy by blocking the STAT3/ERK1/2/AKT signaling pathway through miRNA-148a-mediated GP130 inhibition.
Features
-
Precise tissue targeting
-
Multiple targeting peptide options
-
Advanced plasmid construction and transfection technology
-
Professional technical support
Drug delivery targeting CVD is a major challenge in the treatment of CVD. It is hopeful that, as an endogenous membrane-type carrier, exosomes can be appropriately modified to have tissue targeting, and play a great therapeutic value as a drug delivery system. Creative Biolabs can provide plasmid construction, plasmid transfection, lentiviral stable transfection, and other genetic engineering technologies to transform exosomes from the source. In addition, we can also provide customized services such as exosome extraction, identification, and functional verification. Please contact us with your needs and ideas to help you move forward with your project.
FAQs
Q: What are the potential applications of heart-targeted exosomes in research?
A: Heart-targeted exosomes have numerous applications in research, including but not limited to, targeted drug delivery for cardiac diseases, gene therapy for heart conditions, studying the mechanisms of heart disease, and regenerative medicine. Their precise targeting capabilities make them a valuable tool for any research involving cardiac tissue.
Q: How do you verify the expression of cardiac-targeting peptides on the surface of exosomes?
A: We use multiple methods to verify the expression of targeting peptides on the exosome surface, including Western blotting and flow cytometry. These techniques allow us to confirm the successful incorporation and correct presentation of the targeting peptides on the exosomes.
Q: Are there any potential off-target effects of heart-targeted exosomes?
A: While our targeting peptides are highly specific to cardiac tissues, off-target effects can vary depending on the specific application and administration route. If needed, we can provide off-target effect testing services for our clients.
Q: Can you provide services for in vivo experimentation involving heart-targeted exosomes?
A: Yes, we offer support for in vivo experimentation, including experimental design, execution, and data analysis. Our team of experts can provide guidance on best practices for administering the exosomes and monitoring their effects, ensuring that you obtain reliable and meaningful results from your studies.
For Research Use Only. Cannot be used by patients.
Related Services:
